Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study

Table 2

Univariate analysis of prognostic factors for overall survival and progression-free survival.

Variables	OS		PFS
	HR (95% CI)	value	HR (95% CI)	value
Gender
Male	1		1
Female	0.879 (0.604, 1.279)	0.500	0.941 (0.667, 1.328)	0.731
Age (years)	0.995 (0.983, 1.007)	0.380	0.994 (0.983, 1.005)	0.278
BCLC classs
C	1		1
B	0.491 (0.352, 0.686)	0.000	0.572 (0.416, 0.786)	0.001
A	0.266 (0.183, 0.386)	0.000	0.487 (0.355, 0.666)	0.000
Hepatitis
Hepatitis B	1		1
Other	0.926 (0.669, 1.283)	0.646	1.037 (0.773, 1.391)	0.809
Child-pugh score
A	1
B	1.019 (0.704, 1.475)	0.920	1.073 (0.766, 1.503)	0.683
TB (µmol/L)	1.004 (0.995, 1.013)	0.353	1.005 (0.997, 1.014)	0.234
Albumin (g/L)	0.989 (0.969, 1.009)	0.261	1.001 (0.981, 1.022)	0.905
PT (s)	0.988 (0.902, 1.083)	0.801	0.969 (0.890, 1.056)	0.476
AST (μmol/L)	1.002 (1.001, 1.003)	0.002	1.001 (1.000, 1.002)	0.007
ALT (μmol/L)	1.000 (0.999, 1.002)	0.728	1.001 (1.000, 1.002)	0.198
PLR	1.003 (1.002, 1.004)	0.000	1.002 (1.001, 1.004)	0.001
NLR	1.032 (1.017, 1.046)	0.000	1.022 (1.007, 1.037)	0.005
Tumor size	1.067 (1.036, 1.099)	0.000	1.058 (1.030, 1.088)	0.000
Tumor number
>3	1		1
≤3	0.846 (0.270, 2.649)	0.774	0.932 (0.298, 2.917)	0.903
α-Fetoprotein level
≥400 ng/mL	1		1
<400 ng/ml	0.958 (0.726, 1.265)	0.764	0.950 (0.734, 1.229)	0.695
Ascites
Present	1		1
Absent	0.923 (0.624, 1.366)	0.688	0.990 (0.688, 1.424)	0.955
TACE sessions	0.701 (0.646, 0.761)	0.000	0.889 (0.835, 0.946)	0.000
Treatment method
D-TACE + Liopodol	1		1
D-TACE	1.610 (1.003, 2.583)	0.049	1.323 (0.866, 2.019)	0.195

Note. OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; SD: standard deviation; BCLC: barcelona clinical liver cancer; TB: total bilirubin; PT: prothrombin time; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; D-TACE: drug-elutingbeads-transcatheter arterial chemoembolization.